Skip to main content
Log in

Glibenclamide protects against thioacetamide-induced hepatic damage in Wistar rat: investigation on NLRP3, MMP-2, and stellate cell activation

  • Original Article
  • Published:
Naunyn-Schmiedeberg's Archives of Pharmacology Aims and scope Submit manuscript

Abstract

Glibenclamide (GLB), most widely used in the treatment of type II diabetes mellitus, inhibits K+ATP channel in pancreatic-β cells and releases insulin, while thioacetamide (TAA) is a well-known hepatotoxicant and most recommended for the induction of acute and chronic liver disease. The purpose of this study was to evaluate the hepatoprotective potential of GLB against TAA-induced hepatic damage in Wistar rats. TAA (200 mg/kg, ip, twice weekly) and GLB (1.25, 2.5, and 5 mg/kg/day, po) were administered for 6 consecutive weeks. Different biochemical, DNA damage, histopathological, TEM, immunohistochemical, and western blotting parameters were evaluated. GLB treatment has no effects on the TAA-induced significant decrease in body and liver weights. TAA treatment significantly increased liver index and treatment with GLB has no effect the same. TAA treatment altered the liver morphology, whereas treatment with GLB normalized the alteration in morphology. Further, significant increase in oxidative stress, apoptosis, and DNA damage was found in TAA-treated animals and GLB treatment significantly reduced these effects. TAA-induced plasma transaminases and serum ALP levels were significantly restored by GLB. Furthermore, histopathological findings showed the presence of lymphocyte infiltration, collagen deposition, bridging fibrosis, degeneration of portal triad, and necrosis in TAA-treated animals and GLB intervention significantly reduced the same. TEM images revealed that GLB significantly normalized the hepatic stellate cell morphology as well as restored the number of lipid droplets. GLB treatment significantly downregulated the expressions of TGF-β1, α-SMA, NLRP3, ASC, caspase-1, and IL-1β, and upregulated MMP-2 and catalase against TAA-induced liver damage. The outcomes of the present study confirmed that GLB ameliorated the liver damage induced by TAA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10

Similar content being viewed by others

Abbreviations

ALP:

Alkaline phosphatase

ALT:

Alanine transaminase

ASC:

Apoptosis-associated speck-like protein containing a caspase-recruiting domain

AST:

Aspartate transaminase

ATP:

Adenosine triphosphate

CYP2E1:

Cytochrome P450 2E1

DAB:

3,3′-Diaminobenzidine

DMSO:

Dimethyl sulfoxide

ECM:

Extracellular matrix

GLB:

Glibenclamide

HSC:

Hepatic stellate cell

IL:

Interleukin

IL-1β:

Interleukin-1 beta

ip:

Intraperitoneal

MT:

Masson’s trichrome

MMP-2:

Matrix metalloproteinase-2

NLRP3:

NACHT, LRR, and PYD domains-containing protein 3

TMO:

Tail moment olive

PAS:

Periodic acid-Schiff base

po:

Per os (oral administration)

PSR:

Picro Sirius Red

PSRF:

PSR with fast green FCF

SOD:

Superoxide dismutase

T2DM:

Type II diabetes mellitus

TAA:

Thioacetamide

TEM:

Transmission electron microscopy

TGF-β1:

Transforming growth factor beta1

TL:

Tail length

TM:

Tail moment

TUNEL:

Terminal deoxynucleotidyl transferase dUTP nick end labeling assay

US-FDA:

United States Food and Drug Administration

WHO:

World Health Organization

α-SMA:

Alpha-smooth muscle actin

γ-GT:

γ-Glutamyl transferase

References

Download references

Acknowledgements

We wish to acknowledge the financial assistance received from National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar, India, for carrying out the above experimentation. The authors would like to acknowledge Mr. Vinod Kumar for TEM image analysis. We are also grateful to Dr. Sabbir Khan, Dr. Krishna Prahlad Maremanda, and Dr. Venkateswara Rao Amara for their timely advice and technical support.

Author information

Authors and Affiliations

Authors

Contributions

DKD conceived, conducted the experiments, analyzed the data, and wrote the manuscript. GBJ conceived the idea, reviewed the manuscript, and administered the project. Finally, both the authors have read and approved the manuscript.

Corresponding author

Correspondence to G. B. Jena.

Ethics declarations

The experimental protocol was approved by the Institutional Animal Ethics Committee (IAEC) against approval number IAEC/16/54.

Conflict of interest

The authors declare that they have no conflict of interest.

Electronic supplementary material

ESM 1

(DOCX 17354 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dwivedi, D.K., Jena, G.B. Glibenclamide protects against thioacetamide-induced hepatic damage in Wistar rat: investigation on NLRP3, MMP-2, and stellate cell activation. Naunyn-Schmiedeberg's Arch Pharmacol 391, 1257–1274 (2018). https://doi.org/10.1007/s00210-018-1540-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00210-018-1540-2

Keywords

Navigation